B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare prevalence of SLE have posed difficulties in trial design and contributed to a slow pace for drug development. The anti-BAFF monocl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.00316/full |
| _version_ | 1819064903891156992 |
|---|---|
| author | Ioannis Parodis Ioannis Parodis Marit Stockfelt Christopher Sjöwall |
| author_facet | Ioannis Parodis Ioannis Parodis Marit Stockfelt Christopher Sjöwall |
| author_sort | Ioannis Parodis |
| collection | DOAJ |
| description | B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare prevalence of SLE have posed difficulties in trial design and contributed to a slow pace for drug development. The anti-BAFF monoclonal antibody belimumab is still the sole targeted therapy licensed for SLE, lending credence to the widely accepted notion that B cells play central roles in lupus pathogenesis. However, more therapeutic agents directed toward B cells or B cell-related pathways are used off-label or have been trialed in SLE. The anti-CD20 monoclonal antibody rituximab has been used to treat refractory SLE during the last two decades, and the anti-type I IFN receptor anifrolumab is currently awaiting approval after one phase III clinical trial which met its primary endpoint and one phase III trial which met key secondary endpoints. While the latter does not directly affect the maturation and antibody production activity of B cells, it is expected to affect the contribution of B cells in proinflammatory cytokine excretion. The proteasome inhibitor bortezomib, primarily directed toward the plasma cells, has been used in few severe cases as an escape regimen. Collectively, current clinical experience and primary results of ongoing clinical trials prophesy that B cell therapies of selective targets will have an established place in the future personalized therapeutic management of lupus patients. |
| first_indexed | 2024-12-21T15:37:58Z |
| format | Article |
| id | doaj.art-e6abed09fd0c460dbd62531d68734057 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-21T15:37:58Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e6abed09fd0c460dbd62531d687340572022-12-21T18:58:36ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-07-01710.3389/fmed.2020.00316554391B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical PracticeIoannis Parodis0Ioannis Parodis1Marit Stockfelt2Christopher Sjöwall3Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, SwedenRheumatology, Karolinska University Hospital, Stockholm, SwedenDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, SwedenDivision of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, SwedenB cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare prevalence of SLE have posed difficulties in trial design and contributed to a slow pace for drug development. The anti-BAFF monoclonal antibody belimumab is still the sole targeted therapy licensed for SLE, lending credence to the widely accepted notion that B cells play central roles in lupus pathogenesis. However, more therapeutic agents directed toward B cells or B cell-related pathways are used off-label or have been trialed in SLE. The anti-CD20 monoclonal antibody rituximab has been used to treat refractory SLE during the last two decades, and the anti-type I IFN receptor anifrolumab is currently awaiting approval after one phase III clinical trial which met its primary endpoint and one phase III trial which met key secondary endpoints. While the latter does not directly affect the maturation and antibody production activity of B cells, it is expected to affect the contribution of B cells in proinflammatory cytokine excretion. The proteasome inhibitor bortezomib, primarily directed toward the plasma cells, has been used in few severe cases as an escape regimen. Collectively, current clinical experience and primary results of ongoing clinical trials prophesy that B cell therapies of selective targets will have an established place in the future personalized therapeutic management of lupus patients.https://www.frontiersin.org/article/10.3389/fmed.2020.00316/fullB cellssystemic lupus erythematosustherapybiologicsplasma cellsplasmablasts |
| spellingShingle | Ioannis Parodis Ioannis Parodis Marit Stockfelt Christopher Sjöwall B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice Frontiers in Medicine B cells systemic lupus erythematosus therapy biologics plasma cells plasmablasts |
| title | B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice |
| title_full | B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice |
| title_fullStr | B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice |
| title_full_unstemmed | B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice |
| title_short | B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice |
| title_sort | b cell therapy in systemic lupus erythematosus from rationale to clinical practice |
| topic | B cells systemic lupus erythematosus therapy biologics plasma cells plasmablasts |
| url | https://www.frontiersin.org/article/10.3389/fmed.2020.00316/full |
| work_keys_str_mv | AT ioannisparodis bcelltherapyinsystemiclupuserythematosusfromrationaletoclinicalpractice AT ioannisparodis bcelltherapyinsystemiclupuserythematosusfromrationaletoclinicalpractice AT maritstockfelt bcelltherapyinsystemiclupuserythematosusfromrationaletoclinicalpractice AT christophersjowall bcelltherapyinsystemiclupuserythematosusfromrationaletoclinicalpractice |